Analysts expect revenue increase Biogen

Over the current book year the total revenue will be 13,2 billion USD (consensus estimates). This is slightly more than 2017's revenue of 12,27 billion USD.

Historical revenues and results Biogen plus estimates 2018

The analysts expect for 2018 a net profit of 5,22 billion USD. For this year most of the analysts expect a profit per share of 25,3 USD. So the price/earnings-ratio equals 12,66.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a poor 0,5 percent.

Newest target prices around 381 USD

The most recent recommendations for the biotech company are from Sanford C. Bernstein & Co, Stifel and ABN AMRO.

Biogen 's market value equals around 69,18 billion . The Biogen stock was the past 12 months quite unstable. Since last October the stock is 5 percent lower. This year the stock price moved between 249 and 389 dollar. Since 2008 the stock price is almost 754 percent higher.

On Friday the stock closed at 320,41 USD.

Historical stock prices Biogen from 2007 till 2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.